FDA Approves TTFields Plus Chemo in Locally Advanced Pancreatic Cancer
The U.S. FDA granted approval for a new combination treatment, TTFields and chemotherapy, for locally advanced pancreatic cancer. This decision marks an important development in the fight against this deadly disease.
FDA Issues Partial Clinical Hold on Lorigerlimab Trial in Gynecologic Cancers
A clinical trial testing Lorigerlimab in treating gynecologic cancers has been temporarily halted by the FDA. The reason and potential implications of this decision remain under investigation.
Refining Management of Immune-Checkpoint Inhibitor Toxicities in Melanoma
The management of immune-checkpoint inhibitor toxicities in melanoma treatment is undergoing significant refinement. Improved methods will facilitate better patient outcomes.
FDA Grants Fast Track Designation to SRN-101 for Recurrent High-Grade Glioma
SRN-101, a proposed treatment for recurrent high-grade glioma, has been given fast track designation by the FDA. This status will expedite its clinical testing and potential approval process.
Novel Small Molecule Shows Early Activity in Pretreated Multiple Myeloma
An unprecedented small molecule has shown early activity in the treatment of pretreated multiple myeloma. This discovery offers potential new paths of treatment.
Comparing Quality of Life Outcomes with Protons vs Photons in OPSCC
The quality of life outcomes between Proton and Photon treatment methods for OPSCC has been compared. Results and implications of this comparison continue to be analysed.
